Stay updated with breaking news from Multiple Sclerosis Relapse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.
Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.
"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.
Contrary to previous research, a new study suggests fertility treatments pose little risk of MS relapse in women who undergo fertility treatments, suggesting it may be time for new clinical guidance.
Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say that's both a blessing and problem.